Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.93 -0.11 (-0.36%)
Streaming Delayed Price Updated: 11:54 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
From Legend Biotech Corporation
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) shares mo... 
Via Benzinga
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Legend Biotech to Host R&D Day on October 18, 2021
From Legend Biotech
Via Business Wire
Week In Review: Everest Announces Two In-Licensings With Total Value Of $1 Billion
Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. Shanghai Everest Medicines announced a $500 million two-part deal... 
Via Talk Markets
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday morning, 54 companies achieved new highs for the year. Noteworthy Mentions: The largest company by market cap to set a new 52-week high was Costco... 
Via Benzinga
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
Via Benzinga
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US
Legend Biotech Corporation (NASDAQ: LEGN) has announced that the FDA accepted for priority review the marketing application submitted by Janssen Biotech Inc... 
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.